Alzheimer’s disease and Aβ pathways
1 Department of Neurology & Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
2 Department of Biotechnology, Manipur University, Chanchipur, Imphal-795003, India.
Review Article
World Journal of Advanced Research and Reviews, 2021, 12(03), 542–544
Article DOI: 10.30574/wjarr.2021.12.3.0740
Publication history:
Received on 22 November 2021; revised on 26 December 2021; accepted on 28 December 2021
Abstract:
Alzheimer's disease (AD) is a neurodegenerative disease which is one of the major health issues globally. It is the 6th cause of death in the United States. Approximately, 60–70% of cases of dementia are caused by AD. The disease advances with age worsening the symptoms that include problems with declining memory, language, mood swings, loss of motivation, self-neglect, and other behavioral issues. AD patients need a long-term health care and hospital services as the disease worsens with the advancing of their age. However, proper medications and treatment is still unavailable as the cause of AD is poorly understood.
Keywords:
Amyloid beta pathway; Alzheimer’s disease; Dementia; Global health; Global economy
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0